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Short Communication
Antibody-dependent-cellular-cytotoxicity against cultured
human breast cancer cells mediated by human effector cells
using monoclonal and polyclonal antibodies
M.E. Gore, R.A. Skilton & R.C. Coombes
Ludwig Institutefor Cancer Research (London Branch), Royal Marsden Hospital, Sutton, Surrey, SM2 SPX.
Most studies to elucidate the role of antibody
dependent cellular cytotoxicity (ADCC) have
examined polyclonal antisera. However, more
recently there have been reports of monoclonal
antibodies being active in such systems (Bernstein et
al., 1980; Herlyn al., 1979). This is important
because monoclonal reagents obviate the inherent
variability and heterogeneity of conventional
antisera and permit a more accurate analysis of the
effector cell populations responsible for ADCC
against a variety of targets. Furthermore, these
advantages enable different groups to compare
results.
Since monoclonal antibodies have been found to
be effective in suppressing the growth of human
tumours in immune-deprived animals (Herlyn et al.,
1980; Bernstein et al., 1980; Kirch & Hammerling,
1981), we decided to investigate an ADCC assay
with a view to using it as a more simple system to
screen monoclonal antibodies for possible clinical
use. To do this we examined killing of human
breast cancer cells comparing polyclonal and
monoclonal antisera. Human peripheral blood
lymphocytes (HPBL) and human bone marrow
were used as sources of effector cells. We
considered the latter to be important in view of the
possibilities of using monoclonal antibodies to kill
cancer cells in bone marrow (Buckman et al., 1982).
The two polyclonal antisera tested were (a) anti-
epithelial membrane antigen (anti-EMA) raised in
rabbits and purified as previously reported (Sloane
& Ormerod, 1981) and (b) an antiserum raised in
mice against the cell line MCF-7. Anti-EMA was
chosen because of its value in detecting metastatic
breast cancer cells in the bone marrow (Dearnaley
et al., 1981). Anti-EMA and anti-MCF-7 were both
used at a dilution of 1/100 in medium (RPMI 1640,
Gibco, containing 2% foetal calf serum, kanomycin
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and amphotericin). Monoclonal antibodies LICR-
LON-Fib-75 (Edwards et al., 1980) and LICR-
LON-R1O (Anstee & Edwards, 1982) were chosen,
the former because of its panepithelial staining and
its role in clearing metastatic breast carcinoma cells
from human bone marrow (Buckman et al., 1982);
this antibody was used at a concentration of
1-2pg/200p1 of medium. LICR-LON-RIO was used
as mouse ascitic fluid at a dilution of 1/100 in
medium. This antiserum reacts with red cell
glycophorin and was used as a control. Normal
non-immunised rabbit serum at a dilution of 1/100
in medium was used as a negative control for the
studies with polyclonal antisera.
[51Cr]-sodium chromate labelled human breast
carcinoma cells were used as target cells (MDA-
MB-231; Cailleau et al., 1974).
HPBL effector cells were obtained from human
volunteers and bone marrow effector cells from
normal human donors. The blood or bone marrow
was diluted 1:3 in PBS, carefully layered onto
Ficoll-Hypaque, density 1.077 and 1.100 respectively
and centrifuged at 500g for 20min. The interface
was collected, washed with medium and the cells
suspended in an appropriate volume ofmedium.
The ADCC assay was performed by pipetting
labelled target cells into 96-well U-bottomed plates
(Microtitre M24 AR) at a concentration of 2 x 104
cells per 50M1 of medium per well, adding 100p1 of
antibody and incubating for 1 h at 4°C. The cells
were then centrifuged at 5OOg for 5min and the
supernatants removed. Different concentrations of
effector cells in 1001 of medium were then added
to each well to give effector cell:target cell ratios
from 1:1 to 200:1. The plates were then incubated
for 4h at 37°C. After this time 50p1 of medium was
added to each well to disturb the cells. The plates
were then spun at 500g for 10min and 120p1 of
supernatant removed and counted in a gamma
counter. Maximum 51Cr-release was obtained by
incubating target cells with 1% NP40. Percentage
specific lysis was calculated in the usual way using878 M.E. GORE et al.
the formula:
%specific lysis=
experimental release-spontaneous release l00
maximum release-spontaneous release
The ability of LICR-LON-Fib-75 to mediate
ADCC was investigated at a variety of effector
cell:target cell (EC:TC) ratios using HPBL. Anti-
EMA was used concurrently at the same EC:TC
ratio in each experiment as a positive control
(Table I). Maximum lysis achieved with LICR-
LON-Fib-75 was 45% at an EC:TC ratio of 100: 1.
In the same experiment at the same EC:TC ratio
anti-EMA produced 61% lysis.
Table I ADCC mediated by HPBL with anti-EMA or
LICR-LON-Fib-75a
Effector cell: Percentage specific lysis
target cell (±s.d.) using:
ratio Anti-EMA LICR-LON-Fib-75
10:1 15.6+2.5 4+2.8
20:1 38.5+2.1 8+1.4
40:1 39+1 9.7+1.5
50:1 58+ 12.8 38.3+5.9
80:1 66+2.8 32+8.4
100:1 61+6.1 45.1+2.3
130:1 65+3.1 8.5+1.9
aEach estimation performed in triplicate.
Mean spontaneous lysis was 10.6+2.9%: controls were
as follows: Target cells (TC) and anti-EMA (4.7+4.5%);
TC and LICR-LON-Fib-75 (0.57+0.97%); TC and HPBL
(2.7+ 1.8% at EC:TC 40: 1; 1.8+2.5% at EC:TC 130: 1).
Neither anti-MCF-7, LICR-LON-R1O nor
normal non-immunised rabbit serum mediated
ADCC at EC:TC ratios of 50:1, 50:1 and 20:1
respectively when HPBL were used.
The ability of LICR-LON-Fib-75 and anti-EMA
to mediate ADCC using normal human marrow as
a source of effector cells was investigated (Table II).
Anti-EMA and LICR-LON-Fib-75 were run
concurrently at the same EC:TC ratio. LICR-
LON-Fib-75 and anti-EMA were also used with
HPBL in each experiment as a positive control for
the assay. When anti-EMA was used with bone
marrow a small lytic effect was demonstrated.
Although the percentage lysis was low (25% at the
highest ET:TC ratio) this was above any control
wells (bone marrow and target cells without
antibody). It can be seen from Table II that bone
marrow did not effect ADCC nearly as well as
HPBL. In the same experiments LICR-LON-Fib-
75 failed to produce any significant lysis above
background levels when bone marrow was used as
the source of effector cells.
HPBL were obtained from each of the bone
marrow donors at the time of their marrow harvest
and assayed for their ADCC effect; the percentage
specific lysis was comparable to that achieved with
HPBL from normal volunteers.
We have found that anti-EMA is a potent
mediator of ADCC when HPBL are used as the
source of effector cells. Although the monoclonal
antibody LICR-LON-Fib-75 will also effect ADCC
when HPBL are used, it does so to a lesser extent.
Anti-EMA and not LICR-LON-Fib-75 will effect
ADCC above control levels, when bone marrow is
used as the source of effector cells. These results
indicate that the failure of an antibody to mediate
Table II ADCC mediated by HPBL or bone marrow with anti-EMA or
LICR-LON-Fib-75a
Percentage specific lysis
Effector cell: (±s.d.) using:
target cell Anti-EMA Anti-EMA LICR-Fib-75 LICR-Fib-75
ratio (HPBL) (bone marrow) (HPBL) (bone marrow)
6:1 ND 5.6+1.5 4.5+2.1 0.4+0.2
20:1 38.5+2.1 6+1 8+1.4 1+1
66:1 66+2.8 6.5+7.8 32+8.5 6+1.4
100:1 61+6.2 18+2.2 45.1+2.3 9.3+2.3
200:1 ND 25.7+4.3 ND 12.5+2
aEach estimation performed in triplicate.
ND=not done.
Mean spontaneous lysis was 8.5+ 1.4%: controls as follows: Target cells
(TC) and anti-EMA (0%); TC and LICR-LON-Fib-75 (2%); TC and
HPBL (0%); TC and bone marrow (1.5+0.7% at EC:TC 66:1; 2.6+0.1%
at EC:TC 100:1; 14.9+0.1% at EC:TC 200:1).ADCC WITH HUMAN EFFECTOR CELLS 879
ADCC with bone marrow is partly a function of the
antiserum used. However, as all assays were
terminated at 4h, there remains the possibility that
the difference in effector capability between bone
marrow and peripheral blood lymphocytes is a
function of reaction kinetics. This has not been
investigated.
Nevertheless, the results obtained using LICR-
LON-Fib-75 are of particular interest since this is
the first monoclonal antibody which has been
shown to be active in an ADCC assay where human
effector cells have been used against human tumour
cell targets and a reasonably high percentage
specific lysis achieved. Previous attempts to
demonstrate ADCC in such a system have not been
successful (Nadler, Stashenko et al., 1980; Dillman,
Sobol et al., 1982).
Mouse bone marrow-derived effector cells have
been shown to mediate ADCC against red blood
cell targets (Berger and Amos, 1977) and tumour
cells (Haskill & Fett, 1976; Bursuker et al., 1982),
but it has not previously been shown that human
bone marrow can be active in an ADCC assay
against human tumour cells. The clinical
significance of this activity is highly speculative but
may merit further investigation particularly when
treatments aimed at clearing malignant cells from
bone marrow, by systemic or in vitro monoclonal
antibody therapy, are proposed.
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References
ANSTEE, D.J. & EDWARDS, P.A.W. (1982). Monoclonal
antibodies to human erythrocytes. Eur. J. Immunol.,
12, 228.
BERGER, A.E. & AMOS, D.B. (1977). A comparison of
antibody-dependent cellular cytotoxicity (ADCC)
mediated by murine and human lymphoid cell
populations. Cell. Immunol., 33, 277.
BERSTEIN, I.D., TAM, M.R. & NOWINSKI, R.C. (1980).
Mouse leukaemia therapy with monoclonal antibodies
against a thymus differentiation antigen. Science, 207,
68.
BUCKMAN, R., McILHINNEY, R.A.J., SHEPHERD, V.,
PATEL, S., COOMBES, R.C. & NEVILLE, A.M. (1982).
Elimination of carcinoma cells from human bone
marrow. Lancet, fi, 1428.
BURSUKER, I., GOLDMAN, R., SCHADE, U. &
LOHMANN-MATTHES, M.L. (1982). Differences in
antibody-dependent cellular cytoxicity against tumour
cells in in vitro differentiating mononuclear phagocytes
from bone marrows of normal and inflamed mice. Cell
Immunol., 68, 53.
CAILLEAU, R., YOUNG, R., OLIVE, M. & REEVES, W.J.
(1974). Breast tumour cell lines from pleural effusions.
J. Natl Cancer Inst., 53, 661.
DEARNALEY, D.P., SLOANE, J.P., ORMEROD, M.G. & 7
others. (1981). Increased detection of mammary
carcinoma cells in marrow swears using antisera to
epithelial membrane antigen. Br. J. Cancer, 44, 85.
DILLMAN, R.O., SOBOL, R.E., COLLINS, H.,
BEAUREGARD, J. & ROYSTON, I. (1982). In:
Hybridomas in Cancer Diagnosis and Treatment. (Eds.
Mitchell & Oettgen). New York: Raven Press, p. 151.
EDWARDS, P.A.W., FOSTER, C.S. & McILHINNEY, R.A.J.
(1980). Monoclonal antibodies to teratomas and
breast. Transpl. Proc., 12, 398.
HASKILL, J.S. & FETT, J.W. (1976). Possible evidence for
antibody-dependent macrophage cytotoxicity against
murine adenocarcinoma cells in vivo. J. Immunol., 117,
1992.
HERLYN, D., HERLYN, M., STEPLEWSKI, Z. &
KOPROWSKI, H. (1979). Monoclonal antibodies in cell-
mediated cytotoxicity against human melanoma and
colorectal carcinoma. Eur. J. Immunol., 9, 657.
HERLYN, D.M., STEPLEWSKI, Z., HERLYN, M.F. &
KOPROWSKI, H. (1980). Inhibition of growth of
colorectal carcinoma in nude mice by monoclonal
antibody. Cancer Res., 40, 717.
KIRCH, M.E. & HAMMERLING, U. (1981).
Immunotherapy of mouse leukaemias by monoclonal
antibodies. 1. Effect of passively administered antibody
on growth in transplanted tumour cells. J. Immunol.,
127, 805.
NADLER, L.M., STASHENKO, P., HARDY, R., KAPLAN,
W.D., BUTTON, L.N., KUFE, D.W., ANTMAN, K.H. &
SCHLOSSMAN, S.F. (1980). Serotherapy of a patient
with a monoclonal antibody directed against a human
lymphoma-associated antigen. Cancer Res., 40, 3147.
SLOANE, J.P. & ORMEROD, M.G. (1981). Distribution of
epithelial membrane antigen in normal and neoplastic
tissues and its value in diagnostic tumour pathology.
Cancer, 47, 1786.